Lead Editor:
Dr Stavros Papadakos,
National and Kapodistrian University of Athens,
Greece
Aim and Scope:
The special issue "Emerging Immunotherapies for Gastrointestinal Cancers: From Bench to Bedside" aims to provide a comprehensive overview of the latest developments, innovative approaches, and ongoing challenges in the field of immunotherapy for gastrointestinal cancers, including colorectal, gastric, pancreatic, liver, and esophageal cancers. This issue seeks to gather high-quality original research articles, reviews, clinical trials, and case studies that offer insights into the mechanisms, efficacy, and potential side effects of various immunotherapeutic strategies.
Topics of Interest:
Mechanisms of Action: Studies on the molecular and cellular mechanisms underlying the immune response in gastrointestinal cancers.
Biomarkers for Immunotherapy: Identification and validation of predictive biomarkers for response to immunotherapy.
Checkpoint Inhibitors: Efficacy and safety of checkpoint inhibitors (e.g., PD-1, PD-L1, CTLA-4) in gastrointestinal cancers.
Adoptive Cell Therapy: Advances in CAR-T cell therapy and other adoptive cell therapies for gastrointestinal malignancies.
Combination Therapies: Clinical trials and studies on combination therapies involving immunotherapy and other treatment modalities such as chemotherapy, targeted therapy, and radiation.
Tumor Microenvironment: Research on the role of the tumor microenvironment in modulating the immune response and impacting immunotherapy outcomes.
Vaccines and Oncolytic Viruses: Development and clinical application of cancer vaccines and oncolytic viruses.
Novel Immunotherapeutic Agents: Discovery and development of new immunotherapeutic drugs and biologics.
Resistance Mechanisms: Investigation of primary and acquired resistance to immunotherapy and strategies to overcome resistance.
Submission deadline:
23/01/2026
|
Views:
